FRANCISCO JAVIER
SALMERÓN ESCOBAR
Investigador en el periodo 2002-2020
Manuel
Romero-Gómez
Publicaciones en las que colabora con Manuel Romero-Gómez (34)
2021
-
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
2020
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH
Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676
-
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort
Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64
2018
-
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349
-
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))
Gastroenterologia y Hepatologia
-
Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry
Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1495-1502
-
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C
Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948
-
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity
Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270
2016
2015
-
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis
World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174
-
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection
Genes and Immunity, Vol. 16, Núm. 5, pp. 297-300
-
High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods
Journal of Clinical Microbiology, Vol. 53, Núm. 1, pp. 219-226
2014
-
Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study
Gastroenterologia y Hepatologia, Vol. 37, Núm. 1, pp. 1-8
2011
-
Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin
American Journal of Gastroenterology, Vol. 106, Núm. 7, pp. 1246-1254
-
La respuesta virológica al tratamiento con adefovir dipivoxil predice el desarrollo de resistencias a largo plazo en pacientes con hepatitis crónica B HBeAg negativo previamente no tratados
Gastroenterologia y Hepatologia, Vol. 34, Núm. 2, pp. 69-74
2009
-
Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex
Hepatology, Vol. 49, Núm. 6, pp. 2001-2009